{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:39:19Z","timestamp":1793104759168,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"NIHR Biomedical Research Centre Manchester","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017008","name":"Manchester Cancer Research Centre","doi-asserted-by":"publisher","award":["CTRQQR-2021\\\\100010"],"award-info":[{"award-number":["CTRQQR-2021\\\\100010"]}],"id":[{"id":"10.13039\/501100017008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","phiro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physics and Imaging in Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phro.2026.101103","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:51:01Z","timestamp":1791319861000},"page":"101103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Feasibility of longitudinal prostate R2\u204e measurements in patients undergoing stereotactic ablative radiotherapy on an MRI-linac"],"prefix":"10.1016","volume":"41","author":[{"given":"Chris","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Ezekiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vodathi","family":"Bamunuarachchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ereny","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubhav","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"van Herk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dubec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien J.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phro.2026.101103_bb0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.phro.2026.101103_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2016.02.016","article-title":"How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis","volume":"119","author":"Borras","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0015","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-11-2711","article-title":"Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer","volume":"18","author":"Milosevic","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phro.2026.101103_bb0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrclinonc.2016.162","article-title":"Imaging biomarker roadmap for cancer studies","volume":"14","author":"O\u2019Connor","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0025","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ijrobp.2018.06.023","article-title":"The use of quantitative imaging in radiation oncology: a quantitative imaging network (QIN) perspective","volume":"102","author":"Press","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101103_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.615643","article-title":"Quantitative magnetic resonance imaging for biological image-guided adaptive radiotherapy","volume":"10","author":"van Houdt","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0035","doi-asserted-by":"crossref","first-page":"L41","DOI":"10.1088\/1361-6560\/aa9517","article-title":"First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment","volume":"62","author":"Raaymakers","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.phro.2026.101103_bb0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0304-4165(82)90333-6","article-title":"Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field","volume":"714","author":"Thulborn","year":"1982","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phro.2026.101103_bb0045","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2007.01.018","article-title":"Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry\u2014initial observations","volume":"68","author":"Hoskin","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101103_bb0050","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/09553000903043059","article-title":"Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer","volume":"85","author":"Chopra","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.phro.2026.101103_bb0055","article-title":"Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer","volume":"15","author":"Samuel","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-017-0584-7","article-title":"The role of hypofractionated radiotherapy in prostate cancer","volume":"19","author":"Benjamin","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.phro.2026.101103_bb0065","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2019.06.015","article-title":"National costs and resource requirements of external beam radiotherapy: a time-driven activity-based costing model from the ESTRO-HERO project","volume":"138","author":"Defourny","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2023.102652","article-title":"Towards estimating the carbon footprint of external beam radiotherapy","volume":"112","author":"Chuter","year":"2023","journal-title":"Phys Med"},{"key":"10.1016\/j.phro.2026.101103_bb0080","doi-asserted-by":"crossref","first-page":"S1552","DOI":"10.1016\/S0167-8140(22)03715-X","article-title":"PO-1751 integration of R2* mapping in daily prostate MR-Linac workflow for hypoxia characterisation","volume":"170","author":"Bano","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijrobp.2024.09.009","article-title":"Stereotactic radiation therapy for localized prostate cancer: 10-year outcomes from three prospective trials","volume":"121","author":"Kennedy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101103_bb0090","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijrobp.2010.02.060","article-title":"Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI","volume":"80","author":"Alonzi","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101103_bb0095","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/bjc.2011.385","article-title":"Androgen deprivation therapy as adjuvant\/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments","volume":"105","author":"Payne","year":"2011","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.phro.2026.101103_bb0100","article-title":"Patient experience preparing for prostate cancer radiotherapy","volume":"33","author":"Alexander","year":"2025","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0105","first-page":"744","article-title":"Statistics notes: measurement error","volume":"313","author":"Bland","year":"1996","journal-title":"Brit Med J"},{"key":"10.1016\/j.phro.2026.101103_bb0110","series-title":"Experimental design and the analysis of variance","first-page":"125","article-title":"Repeated measures analysis of variance","author":"Leik","year":"1997"},{"key":"10.1016\/j.phro.2026.101103_bb0115","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/0284186X.2022.2062682","article-title":"Radiation-induced prostate swelling during SBRT of the prostate","volume":"61","author":"Vanhanen","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.radonc.2021.12.037","article-title":"Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: a post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy","volume":"167","author":"Ma","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00335-018-9777-0","article-title":"Radiation, inflammation and the immune response in cancer","volume":"29","author":"McKelvey","year":"2018","journal-title":"Mamm Genome"},{"key":"10.1016\/j.phro.2026.101103_bb0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.urolonc.2009.03.024","article-title":"Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy","volume":"29","author":"Langenhuijsen","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.phro.2026.101103_bb0135","first-page":"5027","article-title":"Diffusion-weighted MRI provides a useful biomarker for evaluation of radiotherapy efficacy in patients with prostate cancer","volume":"37","author":"Wu","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.phro.2026.101103_bb0140","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2214\/AJR.12.8510","article-title":"Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management","volume":"198","author":"Verma","year":"2012","journal-title":"Am J Roentgenol"}],"container-title":["Physics and Imaging in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626002034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626002034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:30:44Z","timestamp":1793104244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405631626002034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S2405631626002034"],"URL":"https:\/\/doi.org\/10.1016\/j.phro.2026.101103","relation":{},"ISSN":["2405-6316"],"issn-type":[{"value":"2405-6316","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of longitudinal prostate R2\u204e measurements in patients undergoing stereotactic ablative radiotherapy on an MRI-linac","name":"articletitle","label":"Article Title"},{"value":"Physics and Imaging in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phro.2026.101103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101103"}}